These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16236604)

  • 1. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function.
    Feuring M; Harenberg J; Peiter A; Ganschow A; Ruf A; Losel R; Wehling M; Schultz A
    Platelets; 2005 Nov; 16(7):430-4. PubMed ID: 16236604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PFA-100R cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations.
    Feuring M; Ruf A; Schultz A; Wehling M
    Platelets; 2010; 21(3):176-82. PubMed ID: 20121459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.
    Tucci MA; Ganter MT; Hamiel CR; Klaghofer R; Zollinger A; Hofer CK
    J Thorac Cardiovasc Surg; 2006 Jun; 131(6):1314-22. PubMed ID: 16733164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian variation of platelet function measured with the PFA-100.
    Feuring M; Wehling M; Ruf A; Schultz A
    Platelets; 2009 Nov; 20(7):466-70. PubMed ID: 19852684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
    Derhaschnig U; Pachinger C; Jilma B
    Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
    Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
    Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100.
    Cesar JM; de Miguel D; García Avello A; Burgaleta C
    Am J Clin Pathol; 2005 May; 123(5):772-7. PubMed ID: 15981818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the antagonism of von Willebrand factor but not fibrinogen by platelet alphaIIbbeta3 antagonists with prolongation of bleeding time.
    Aoki T; Tomiyama Y; Honda S; Mihara K; Yamanaka T; Okubo M; Moriguchi A; Mutoh S
    J Thromb Haemost; 2005 Oct; 3(10):2307-14. PubMed ID: 16150045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
    Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
    Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
    Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
    Goto S; Tamura N; Ishida H; Ruggeri ZM
    J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin.
    Takahashi S; Ushida M; Komine R; Shimizu A; Uchida T; Ishihara H; Shibano T; Watanabe G; Ikeda Y; Murata M
    Thromb Res; 2007; 119(4):517-24. PubMed ID: 16793119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.
    Haubelt H; Anders C; Vogt A; Hoerdt P; Seyfert UT; Hellstern P
    Br J Haematol; 2005 Sep; 130(5):759-67. PubMed ID: 16115134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation.
    Yomo T; Serna DL; Powell LL; Wang D; Wilson SE; Ishimaru S; Chen JC
    Artif Organs; 2000 May; 24(5):355-61. PubMed ID: 10848676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of reduced factor VIII with impaired platelet reactivity to adrenalin and collagen after total thyroidectomy.
    Palareti G; Biagi G; Legnani C; Bianchi D; Serra D; Savini R; Coccheri S
    Thromb Haemost; 1989 Dec; 62(4):1053-6. PubMed ID: 2533412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.